Adriana Herrera1, Mary Ellen Vajravelu1,2, Stephanie Givler1, Lauren Mitteer1, Catherine M Avitabile2,3, Katherine Lord1,2, Diva D De León1,2. 1. Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 2. Department of Pediatrics, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 3. Division of Cardiology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Abstract
Context: Diazoxide, the only U.S. Food and Drug Administration-approved drug to treat hyperinsulinemic hypoglycemia, has been associated with several adverse events, which has raised concerns about the safety of this drug. Existing reports are limited to small studies and case reports. Objective: To determine prevalence of and clinical factors associated with adverse events in infants and children treated with diazoxide. Design: Retrospective cohort study of children with hyperinsulinism (HI) treated with diazoxide between 2003 and 2014. Setting: The Congenital Hyperinsulinism Center at the Children's Hospital of Philadelphia. Patients: Children and infants with laboratory-confirmed diagnosis of HI. Main Outcome Measures: Prevalence of pulmonary hypertension (PH), edema, neutropenia, thrombocytopenia, and hyperuricemia was determined. Tests of association and logistic regression were used to identify potential risk factors. Results: A total of 295 patients (129 female) met inclusion criteria. The median age at diazoxide initiation was 29 days (interquartile range, 10 to 142 days; n = 226 available start dates); 2.4% of patients were diagnosed with PH after diazoxide initiation. Children with PH (P = 0.003) or edema (P = 0.002) were born at earlier gestational age and more frequently had potential PH risk factors, including respiratory failure and structural heart disease (P < 0.0001 and P = 0.005). Other adverse events included neutropenia (15.6%), thrombocytopenia (4.7%), and hyperuricemia (5.0%). Conclusion: In this large cohort, PH occurred in infants with underlying risk factors, but no identifiable risk profile emerged for other adverse events. The relatively high prevalence of neutropenia, thrombocytopenia, and hyperuricemia suggests the value in proactively screening for these side effects in children treated with diazoxide.
Context:Diazoxide, the only U.S. Food and Drug Administration-approved drug to treat hyperinsulinemic hypoglycemia, has been associated with several adverse events, which has raised concerns about the safety of this drug. Existing reports are limited to small studies and case reports. Objective: To determine prevalence of and clinical factors associated with adverse events in infants and children treated with diazoxide. Design: Retrospective cohort study of children with hyperinsulinism (HI) treated with diazoxide between 2003 and 2014. Setting: The Congenital Hyperinsulinism Center at the Children's Hospital of Philadelphia. Patients: Children and infants with laboratory-confirmed diagnosis of HI. Main Outcome Measures: Prevalence of pulmonary hypertension (PH), edema, neutropenia, thrombocytopenia, and hyperuricemia was determined. Tests of association and logistic regression were used to identify potential risk factors. Results: A total of 295 patients (129 female) met inclusion criteria. The median age at diazoxide initiation was 29 days (interquartile range, 10 to 142 days; n = 226 available start dates); 2.4% of patients were diagnosed with PH after diazoxide initiation. Children with PH (P = 0.003) or edema (P = 0.002) were born at earlier gestational age and more frequently had potential PH risk factors, including respiratory failure and structural heart disease (P < 0.0001 and P = 0.005). Other adverse events included neutropenia (15.6%), thrombocytopenia (4.7%), and hyperuricemia (5.0%). Conclusion: In this large cohort, PH occurred in infants with underlying risk factors, but no identifiable risk profile emerged for other adverse events. The relatively high prevalence of neutropenia, thrombocytopenia, and hyperuricemia suggests the value in proactively screening for these side effects in children treated with diazoxide.
Authors: Linda Steinkrauss; Terri H Lipman; Christine D Hendell; Marsha Gerdes; Paul S Thornton; Charles A Stanley Journal: J Pediatr Nurs Date: 2005-04 Impact factor: 2.145
Authors: Matthew R Timlin; Alexander B Black; Heather M Delaney; Renée I Matos; Candace S Percival Journal: Pediatr Cardiol Date: 2017-06-22 Impact factor: 1.655
Authors: D Vuralli; S Aytac Eyupoglu; N Kandemir; A Ozon; N Gonc; A Alikasifoglu Journal: Acta Endocrinol (Buchar) Date: 2021 Jul-Sep Impact factor: 0.877
Authors: Milena Pizzoferro; Gabriele Masselli; Arianna Maiorana; Emanuele Casciani; Saadi Sollaku; Carlo Dionisi-Vici; Marco Spada; Claudio Altini; Maria Felicia Villani; Vittoria Rufini; Gianfranco Gualdi; Maria Carmen Garganese Journal: Am J Nucl Med Mol Imaging Date: 2022-04-15
Authors: Madeline L Keyes; Helen Healy; Katherine A Sparger; Lucas E Orth; Mayya Geha; Sergei Roumiantsev; Juan D Matute Journal: Pediatrics Date: 2021-02 Impact factor: 7.124
Authors: Elisa De Franco; Cécile Saint-Martin; Klaus Brusgaard; Amy E Knight Johnson; Lydia Aguilar-Bryan; Pamela Bowman; Jean-Baptiste Arnoux; Annette Rønholt Larsen; May Sanyoura; Siri Atma W Greeley; Raúl Calzada-León; Bradley Harman; Jayne A L Houghton; Elisa Nishimura-Meguro; Thomas W Laver; Sian Ellard; Daniela Del Gaudio; Henrik Thybo Christesen; Christine Bellanné-Chantelot; Sarah E Flanagan Journal: Hum Mutat Date: 2020-02-17 Impact factor: 4.878
Authors: Mangala M Soundarapandian; Christine A Juliana; Jinghua Chai; Patrick A Haslett; Kevin Fitzgerald; Diva D De León Journal: PLoS One Date: 2020-07-31 Impact factor: 3.240
Authors: Irene Maffre; Marie Vincenti; Fabienne Dalla Vale; Cyril Amouroux; Oscar Werner; Alexandra Meilhac; Gaelle de Barry; Pascal Amedro Journal: J Clin Res Pediatr Endocrinol Date: 2018-10-23